Share on

Global PEGylated Proteins Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Protein Type, Services, Application, Consumables, End-User & Region - Industry Forecasts (2022 to 2027)

Published: January, 2022
ID: 3223
Pages: 182
Formats: report pdf report excel report power bi report ppt

PEGylated Proteins Market Size (2022 to 2027)

As per our report, the global PEGylated proteins market size is valued at USD 921.84 million in 2022. This market size is estimated to grow USD 1518.67 Million by 2027, projecting a CAGR of 10.50% from 2022 to 2027.

PEGylation is the process of attaching the strands of the polymer PEG to molecules such as peptides, proteins, and antibody fragments that improve the safety and efficiency of many therapeutics. The PEGylated protein is used to treat anemia, kidney diseases, multiple sclerosis, hemophilia, and cancer. The advancement in the PEGylation process has led to the retention and enhancement of favorable properties of the protein that can be used for therapeutics without losing function. The polymer has high biocompatibility and has fewer side effects, increasing the demand for the PEG polymer in the market.


Wide applications range and increasing adoption of PEGylated proteins are primary factors fuelling the global PEGylated proteins market growth.

There are significant advancements in the PEGylated protein techniques, which help create more stable and non-immunogenic therapies, which is expected to boost global PEGylated protein market growth. The technique has excellent applications in cancer treatment as the number of cancer patients is significantly growing. According to the WHO, around 9.6 million people died due to cancer in 2018. The CCN-family protein can be used for the therapy of blood cancer after the PEGylation process. It is one of the factors boosting the PEGylated proteins market.

The increasing awareness about the benefit of PEGylated protein has increased the acceptance of the product worldwide, which is propelling the market growth. There is a lot of research going on the PEGylated protein to improve the drugs and discover other technique applications. The US FDA approves around 17 PEGylated proteins. Increasing disposable income in urban areas is also leveling up the growth rate of the market.


The PEGylation of protein is a complex process where it needs trained persons. Lack of experts is a significant factor impeding the growth rate of the global PEGylated proteins market.

The prolonged use of PEGylation protein product in treatment can cause lysosomal diseases syndrome, anti–PEG IgM antibodies, bioaccumulation, and hypersensitivity, which is a challenge to the market growth. 

Impact of COVID-19 on the global PEGylated Proteins Market:

The COVID-19 disease outbreaks are caused by a novel coronavirus now officially known as extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2). PEGylation is modifying biological molecules by conjugating them with a non-immunogenic polymer and a non-toxic polyethylene glycol to enhance their physicochemical properties. COVID-19 is expected to have a minor effect on the PEGylated Proteins Market. The use of polyethylene glycol (PEG) to precipitate SARS-CoV-2 stocks without ultracentrifugation has been introduced, which could help provide a resource for various coronaviruses. Low concentrations of PEG-IFN-alpha-2a, which inhibit MERS-CoV replication in cell culture, can inhibit SARS-CoV-2 replication. As a result of the comprehensive research conducted using PEGylation technology, the COVID-19 is expected to impact the industry. PEGylation of therapeutic proteins has improved cancer treatment, leukemia, hepatitis C, rheumatoid arthritis, extreme combined immunodeficiency disease, and Crohn's disease, among other chronic diseases. COVD-19 has caused delays in identifying new cancer cases and the timely delivery of cancer patient treatment. As a result, the market has moderate growth during this pandemic.




Market Size Available

2021 to 2027

Base Year


Forecast Period

2022 to 2027

Segments Analysed

By Protein Type, Consumables, Application, End-User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa


This research report on the global PEGylated proteins market has been segmented based on the protein type, consumables, application, end-user, and region.

PEGylated Proteins Market - By Protein Type:

Based on the protein type, the interferon segment generates the highest revenue owing to massive occurrences of infections associated with chemotherapy, developments made by the majority of the key players. Also, increasing viral infections and stubby risk of adverse effects make this segment grow high.

PEGylated Proteins Market - By Consumables:

  • Reagents 
  • PEGylation Kits      

Based on the consumables, the reagents segment is estimated to occupy most of the shares during the PEGylated protein market forecast period. Increasing diseases and also growing disposable income in urban areas are propelling the market growth.

PEGylated Proteins Market - By Application:

  • Chronic Kidney Diseases   
  • Cancer Treatment

Based on the application, the cancer treatment is anticipated to endure commanding over the period due to the standard increase of cancer worldwide. This segment is considered to showcase the quickest growth during the analysis period.

PEGylated Proteins Market - By End-Users:

  • Pharmaceuticals & Biotechnology Companies         
  • CROs          
  • Academic Research Institutes

Based on the End-users analysis, the pharmaceuticals and biotechnology companies segment is cover the maximum share of the global PEGylated proteins market due to huge expenditure on research and development of proteins.

PEGylated Proteins Market - By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Geographically, the North America PEGylated Proteins Market is predicted to lead the global market and had accounted for more than 30% of the share in the global market in 2020. Factors such as increasing usage of biologics such as erythropoietin for treating diseases chronic illness and robust government funds and approvals for research activities drive the North American market. Additionally, an increase in R&D spending on drug discovery at the initial stages is a supporting factor to this regional market growth.

The Europe PEGylated Proteins Market is expected to grow at a promising rate during the forecast period due to increasing awareness about the health and pharmacy, economic strength to obtain costly medicines, and approving reimbursement policies. In Europe, the German market is predicted to lead the EU PEGylated proteins market.

At the same time, Asia-Pacific PEGylated Proteins Market is expected to grow faster during the forecast period. The growth of the APAC market is majorly driven by the Y-O-Y growth in the prevalence of infectious diseases, growing expenditure on healthcare, and rising medical tourism industry.

The Latin America PEGylated Proteins Market is projected to grow at a steady CAGR during the forecast period. The Brazilian market is estimated to lead the Latin American market due to increasing awareness of health-related issues.

The Middle East & Africa PEGylated Proteins Market is estimated to have a slow growth rate between 2020 to 2025 and is majorly driven by the entry of new key players. Of this region, Africa is the fastest-growing nation with the increasing acquisition of protein-based drugs over non-protein-based drugs.


Some of the major companies dominating the global PEGylated Proteins market profiled in the report are Laysan Bio, Ltd., Iris Biotech GmbH, Biomatrik Inc., Quanta BioDesign Ltd., Cealares GmbH, Creative PEGworks, Jenkem Technology USA Inc., NOF Corporation, Thermo Fisher Scientific Inc., and Merck Millipore.


Please wait. . . . Your request is being processed

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample